vs
MediWound Ltd.（MDWD）与Niagen Bioscience, Inc.（NAGE）财务数据对比。点击上方公司名可切换其他公司
Niagen Bioscience, Inc.的季度营收约是MediWound Ltd.的5.9倍（$33.8M vs $5.7M）。Niagen Bioscience, Inc.净利率更高（12.2% vs -233.3%，领先245.5%）。Niagen Bioscience, Inc.同比增速更快（16.2% vs 12.7%）
MediWound Ltd.是一家聚焦烧伤护理、慢性创面治疗及软组织修复领域的生物制药企业，研发、生产及销售创新创面护理产品，主要面向北美、欧洲及亚洲市场的医院、医疗机构及患者提供服务。
Niagen Bioscience（原名为ChromaDex）是一家成立于1999年，总部位于加利福尼亚州洛杉矶的生物科技公司。公司业务涵盖标准品、膳食补充剂以及原料技术开发多个领域，目前在纳斯达克挂牌上市。
MDWD vs NAGE — 直观对比
营收规模更大
NAGE
是对方的5.9倍
$5.7M
营收增速更快
NAGE
高出3.4%
12.7%
净利率更高
NAGE
高出245.5%
-233.3%
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.7M | $33.8M |
| 净利润 | $-13.3M | $4.1M |
| 毛利率 | 23.5% | 64.1% |
| 营业利润率 | -100.1% | 12.1% |
| 净利率 | -233.3% | 12.2% |
| 营收同比 | 12.7% | 16.2% |
| 净利润同比 | -111.2% | -42.4% |
| 每股收益（稀释后） | $-1.23 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDWDNAGE
| Q4 25 | — | $33.8M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | $5.7M | $31.1M | ||
| Q1 25 | — | $30.5M | ||
| Q4 24 | — | $29.1M | ||
| Q3 24 | — | $25.6M | ||
| Q2 24 | $5.1M | $22.7M | ||
| Q1 24 | — | $22.2M |
净利润MDWDNAGE
| Q4 25 | — | $4.1M | ||
| Q3 25 | — | $4.6M | ||
| Q2 25 | $-13.3M | $3.6M | ||
| Q1 25 | — | $5.1M | ||
| Q4 24 | — | $7.2M | ||
| Q3 24 | — | $1.9M | ||
| Q2 24 | $-6.3M | $-15.0K | ||
| Q1 24 | — | $-492.0K |
毛利率MDWDNAGE
| Q4 25 | — | 64.1% | ||
| Q3 25 | — | 64.5% | ||
| Q2 25 | 23.5% | 65.0% | ||
| Q1 25 | — | 63.4% | ||
| Q4 24 | — | 62.5% | ||
| Q3 24 | — | 63.5% | ||
| Q2 24 | 8.8% | 60.2% | ||
| Q1 24 | — | 60.7% |
营业利润率MDWDNAGE
| Q4 25 | — | 12.1% | ||
| Q3 25 | — | 12.5% | ||
| Q2 25 | -100.1% | 10.2% | ||
| Q1 25 | — | 15.7% | ||
| Q4 24 | — | 24.4% | ||
| Q3 24 | — | 6.3% | ||
| Q2 24 | -88.6% | -1.1% | ||
| Q1 24 | — | -3.3% |
净利率MDWDNAGE
| Q4 25 | — | 12.2% | ||
| Q3 25 | — | 13.5% | ||
| Q2 25 | -233.3% | 11.6% | ||
| Q1 25 | — | 16.6% | ||
| Q4 24 | — | 24.6% | ||
| Q3 24 | — | 7.3% | ||
| Q2 24 | -124.5% | -0.1% | ||
| Q1 24 | — | -2.2% |
每股收益（稀释后）MDWDNAGE
| Q4 25 | — | $0.05 | ||
| Q3 25 | — | $0.05 | ||
| Q2 25 | $-1.23 | $0.04 | ||
| Q1 25 | — | $0.06 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | — | $0.02 | ||
| Q2 24 | $-0.68 | $0.00 | ||
| Q1 24 | — | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $20.1M | $76.5M |
| 总资产 | $67.0M | $106.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MDWDNAGE
| Q4 25 | — | — | ||
| Q3 25 | — | $64.1M | ||
| Q2 25 | $1.1M | $60.3M | ||
| Q1 25 | — | $55.5M | ||
| Q4 24 | — | $44.5M | ||
| Q3 24 | — | $32.2M | ||
| Q2 24 | $3.8M | $27.7M | ||
| Q1 24 | — | $27.4M |
股东权益MDWDNAGE
| Q4 25 | — | $76.5M | ||
| Q3 25 | — | $70.7M | ||
| Q2 25 | $20.1M | $64.2M | ||
| Q1 25 | — | $55.3M | ||
| Q4 24 | — | $46.1M | ||
| Q3 24 | — | $34.4M | ||
| Q2 24 | $17.9M | $30.7M | ||
| Q1 24 | — | $29.0M |
总资产MDWDNAGE
| Q4 25 | — | $106.4M | ||
| Q3 25 | — | $98.1M | ||
| Q2 25 | $67.0M | $91.5M | ||
| Q1 25 | — | $81.3M | ||
| Q4 24 | — | $68.3M | ||
| Q3 24 | — | $56.5M | ||
| Q2 24 | $57.3M | $54.0M | ||
| Q1 24 | — | $54.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-5.8M | $679.0K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.16× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MDWDNAGE
| Q4 25 | — | $679.0K | ||
| Q3 25 | — | $3.7M | ||
| Q2 25 | $-5.8M | $1.3M | ||
| Q1 25 | — | $7.9M | ||
| Q4 24 | — | $8.6M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | $-3.6M | $-264.0K | ||
| Q1 24 | — | $295.0K |
现金转化率MDWDNAGE
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.81× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 1.56× | ||
| Q4 24 | — | 1.20× | ||
| Q3 24 | — | 1.86× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MDWD
暂无分部数据
NAGE
| TRUNIAGEN Consumer Product | $27.5M | 81% |
| Ingredients Segment | $5.7M | 17% |
| Other | $694.0K | 2% |
